HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $42 to $50.
November 10, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals' price target has been raised from $42 to $50 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target indicates that the analyst sees potential for the stock's price to increase. This, combined with the maintained 'Buy' rating, suggests a positive outlook for Tarsus Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100